Results 91 to 100 of about 576,758 (217)

EGFR/ERBB receptors differentially modulate sebaceous lipogenesis [PDF]

, 2015
The roles of the epidermal growth factor receptor (EGFR) in sebaceous glands remain poorly explored. We show that human sebocytes express EGFR and lower levels of ERBB2 and ERBB3, all receptors being downregulated after the induction of lipid synthesis ...
Ludovici, Matteo, Dahlhoff, Maik, Picardo, Mauro, Camera, Emanuela, Leonhardt, Heinrich, Schneider, Marlon R., Zouboulis, Christos C., Müller, Udo   +7 more
core   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Dysregulation of Neuregulin-1/ErbB signaling in the hippocampus of rats after administration of doxorubicin

Drug Design, Development and Therapy, 2018
Dehua Liao,1,2 Yujin Guo,3 Daxiong Xiang,2 Ruili Dang,3 Pengfei Xu,3 Hualin Cai,2 Lizhi Cao,1 Pei Jiang3 1Department of Pharmacy, Hunan Cancer Hospital, 2Department of Pharmacy, Institute of Clinical Pharmacy & Pharmacology, Second Xiangya Hospital,
Liao D, Guo Y, Xiang D, Dang R, Xu P, Cai H, Cao L, Jiang P   +7 more
doaj  

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

GENERATION OF pFastBacl-HT AND ISOLATION OF ErbB-2, ErbB-3 AND ErbB-4 cDNAs by RT-PCR [PDF]

, 2000
Over-expression of the ErbB receptor tyrosine kinase subfamily has been implicated in various types of human cancers. In the current study, ErbB-2, ErbB-3, and ErbB-4 tyrosine kinase domain cDNAs were isolated by RT-PCR and subcloned into a pFastBac-HT ...
Diekhans, Stacy
core   +2 more sources

The ectodomain of cadherin-11 binds to erbB2 and stimulates Akt phosphorylation to promote cranial neural crest cell migration.

PLoS ONE, 2017
During development, a multi-potent group of cells known as the cranial neural crest (CNC) migrate to form craniofacial structures. Proper migration of these cells requires proteolysis of cell adhesion molecules, such as cadherins.
Ketan Mathavan, Vikram Khedgikar, Vanessa Bartolo, Dominique Alfandari   +3 more
doaj   +1 more source

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI‐Platinum Therapy (WJOG14120L)

Cancer Science, EarlyView.
WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka, Keita Mori, Nobuhisa Ishikawa, Hiroaki Kanemura, Koichi Azuma, Yukihiro Toi, Hiroshi Handa, Yosuke Tamura, Hiroaki Akamatsu, Haruko Daga, Masafumi Yamaguchi, Teppei Yamaguchi, Yuki Sato, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Takayasu Kurata   +15 more
wiley   +1 more source

Structure-function analysis of nucleolin and ErbB receptors interactions.

PLoS ONE, 2009
BackgroundThe ErbB receptor tyrosine kinases and nucleolin are major contributors to malignant transformation. Recently we have found that cell-surface ErbB receptors interact with nucleolin via their cytoplasmic tail.
Keren Farin, Ayelet Di Segni, Adam Mor, Ronit Pinkas-Kramarski   +3 more
doaj   +1 more source

Periodontitis and metabolic dysfunction‐associated steatotic liver disease

Periodontology 2000, EarlyView.
Abstract Objective Periodontitis is a chronic inflammatory disease with systemic effects that extend beyond the oral cavity and contribute to systemic immune and metabolic dysregulation. Chronic liver diseases, particularly metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive phenotypes, have emerged as major global ...
Rafael Scaf de Molon, Erica Dorigatti de Avila, Davi da Silva Barbirato, Mariana Fampa Fogacci, Jamil Awad Shibli, Anton Sculean, Alpdogan Kantarci   +6 more
wiley   +1 more source

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

Experimental Hematology & Oncology, 2018
Background Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer. Both ERBB2 (HER2) and ERBB3 (HER3) belong to the same family of receptor tyrosine kinases. Dimerization of
John D. Strickley, Aaron C. Spalding, M. Tye Haeberle, Timothy Brown, Don A. Stevens, Jae Jung   +5 more
doaj   +1 more source